ACADIA Pharmaceuticals Inc. (ACAD)
NASDAQ: ACAD · Real-Time Price · USD
16.87
+0.14 (0.84%)
At close: Dec 20, 2024, 4:00 PM
16.81
-0.06 (-0.36%)
After-hours: Dec 20, 2024, 6:00 PM EST
ACADIA Pharmaceuticals Stock Forecast
Stock Price Forecast
The 17 analysts with 12-month price forecasts for ACAD stock have an average target of 26.53, with a low estimate of 19 and a high estimate of 39. The average target predicts an increase of 57.26% from the current stock price of 16.87.
Analyst Consensus: Buy
* Price targets were last updated on Nov 7, 2024.
Analyst Ratings
The average analyst rating for ACAD stock from 18 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 6 | 6 | 6 | 6 |
| Buy | 8 | 7 | 7 | 6 | 6 | 6 |
| Hold | 5 | 6 | 6 | 7 | 7 | 6 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 19 | 19 | 19 | 19 | 19 | 18 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Needham | Needham | Strong Buy Reiterates $28 | Strong Buy | Reiterates | $28 | +65.98% | Nov 7, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $27 | Strong Buy | Reiterates | $27 | +60.05% | Nov 7, 2024 |
| Raymond James | Raymond James | Hold Initiates n/a | Hold | Initiates | n/a | n/a | Oct 10, 2024 |
| Citigroup | Citigroup | Strong Buy Maintains $30 → $23 | Strong Buy | Maintains | $30 → $23 | +36.34% | Aug 8, 2024 |
| UBS | UBS | Strong Buy Maintains $25 → $23 | Strong Buy | Maintains | $25 → $23 | +36.34% | Aug 8, 2024 |
Financial Forecast
Revenue This Year
997.66M
from 726.44M
Increased by 37.34%
Revenue Next Year
1.07B
from 997.66M
Increased by 7.25%
EPS This Year
0.72
from -0.37
EPS Next Year
0.78
from 0.72
Increased by 7.97%
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 1.1B | 1.2B | 1.4B | |||
| Avg | 997.7M | 1.1B | 1.2B | |||
| Low | 928.6M | 955.5M | 1.0B |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 53.2% | 17.6% | 28.3% | |||
| Avg | 37.3% | 7.3% | 10.6% | |||
| Low | 27.8% | -4.2% | -4.3% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 1.23 | 1.31 | 2.36 | |||
| Avg | 0.72 | 0.78 | 1.16 | |||
| Low | 0.41 | 0.24 | 0.42 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | 82.1% | 203.5% | |||
| Avg | - | 8.0% | 49.4% | |||
| Low | - | -67.4% | -45.9% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.